SAMSARA BIOCAPITAL LLC
Q4 2022 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001744967
· CRD 288114
· SEC-registered investment adviser
$464.6M Reported Value Total
SAMSARA BIOCAPITAL, LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $1,365,987,964, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $2.3B gross asset value
Venture Capital Fund: $2.3B
Source: Form ADV filed 2026-10-28
Reported value
$464.6M
Quarter over quarter
+14.3%
Holdings
54
Top-10 concentration
71.4%
Key People
Form ADV owners & control persons
Srinivas Akkaraju
MANAGER OF SAMSARA BIOCAPITAL, LLC
Jonathan Elliot Cohen
CHIEF OPERATING OFFICER
Patrick Michael Dominguez
CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2022 13F record
Q4 2022 13F filing summary
| Period of report | December 31, 2022 |
|---|---|
| Filed | February 14, 2023 |
| Form | 13F-HR |
| Reported value | $464.6M |
| Positions | 54 |
| Change in reported value | +8.3% |
| New positions | 3 |
| Exited positions | 4 |
| Position turnover | 12.1% |
| Top-10 concentration | 71.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
24 | $1.2B |
|
Q1 2026 13F
Filed May 15, 2026
|
22 | $1.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
21 | $969.3M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
27 | $765.9M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $488.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
37 | $560.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
43 | $728.6M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
42 | $520.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
40 | $477.8M |
|
Q1 2024 13F
Filed May 15, 2024
|
39 | $646.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
41 | $642.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
41 | $326.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
47 | $569.7M |
|
Q1 2023 13F
Filed May 15, 2023
|
56 | $483.8M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
54 | $464.6M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
55 | $428.9M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
56 | $375.1M |
|
Q1 2022 13F
Filed May 16, 2022
|
56 | $397.2M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
49 | $515.5M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
46 | $637.3M |
11 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | KDNY CHINOOK THERAPEUTICS INC | $135.2M | 29.11% |
| 2 | SRRK SCHOLAR ROCK HLDG CORP | $41.6M | 8.96% |
| 3 | ACLX ARCELLX INC | $29.7M | 6.38% |
| 4 | GRPH GRAPHITE BIO INC | $28.1M | 6.04% |
| 5 | VRNA VERONA PHARMA PLC | $18.2M | 3.91% |
| 6 | RAIN RAIN ONCOLOGY INC | $18.1M | 3.89% |
| 7 | ISEE IVERIC BIO INC | $17.3M | 3.72% |
| 8 | NKTX NKARTA INC | $17.2M | 3.7% |
| 9 | STRO SUTRO BIOPHARMA INC | $13.5M | 2.91% |
| 10 | 98985W102 ZYMEWORKS INC | $12.7M | 2.74% |
| 11 | ACRS ACLARIS THERAPEUTICS INC | $11.0M | 2.36% |
| 12 | HLVX HILLEVAX INC | $10.2M | 2.2% |
| 13 | RYTM RHYTHM PHARMACEUTICALS INC | $10.1M | 2.16% |
| 14 | PRME PRIME MEDICINE INC | $8.7M | 1.88% |
| 15 | PEPG PEPGEN INC | $8.7M | 1.87% |
| 16 | ICPT INTERCEPT PHARMACEUTICALS IN | $7.9M | 1.71% |
| 17 | DICE DICE THERAPEUTICS INC | $6.3M | 1.36% |
| 18 | LYRA LYRA THERAPEUTICS INC | $5.6M | 1.2% |
| 19 | CNTA CENTESSA PHARMACEUTICALS PLC | $5.3M | 1.13% |
| 20 | JANX JANUX THERAPEUTICS INC | $4.7M | 1.02% |
Values as reported on the Q4 2022 Form 13F. Every position is in the holdings table below.